The Journal of Allergy and Clinical Immunology
Volume 124, Issue 5 , Pages 933-941.e9 , November 2009

Role of sphingosine kinase 1 in allergen-induced pulmonary vascular remodeling and hyperresponsiveness

  • Rainer V. Haberberger, PhD

      Affiliations

    • Department of Anatomy and Histology, Flinders University, Adelaide, Australia
    • These authors contributed equally.
    • ,
  • Christoph Tabeling

      Affiliations

    • Department of Infectious and Respiratory Diseases, Charité–Universitätsmedizin Berlin, Berlin, Germany
    • These authors contributed equally.
    • ,
  • Sue Runciman, PhD

      Affiliations

    • Department of Anatomy and Histology, Flinders University, Adelaide, Australia
    • ,
  • Birgitt Gutbier

      Affiliations

    • Department of Infectious and Respiratory Diseases, Charité–Universitätsmedizin Berlin, Berlin, Germany
    • ,
  • Peter König, MD

      Affiliations

    • Department of Anatomy, Centre for Structural and Cell Biology in Medicine, University of Lübeck, Lübeck, Germany
    • ,
  • Manfred Andratsch, PhD

      Affiliations

    • Department of Physiology and Medical Physics, Innsbruck Medical University, Innsbruck, Austria
    • ,
  • Hartwig Schütte, MD

      Affiliations

    • Department of Infectious and Respiratory Diseases, Charité–Universitätsmedizin Berlin, Berlin, Germany
    • ,
  • Norbert Suttorp, MD

      Affiliations

    • Department of Infectious and Respiratory Diseases, Charité–Universitätsmedizin Berlin, Berlin, Germany
    • ,
  • Ian Gibbins, PhD

      Affiliations

    • Department of Anatomy and Histology, Flinders University, Adelaide, Australia
    • ,
  • Martin Witzenrath, MD

      Affiliations

    • Department of Infectious and Respiratory Diseases, Charité–Universitätsmedizin Berlin, Berlin, Germany
    • Corresponding Author InformationReprint requests: Martin Witzenrath, MD, Charité-Universitätsmedizin Berlin, Department of Infectious and Respiratory Diseases, Charitéplatz 1, 10117 Berlin, Germany.

Received 26 November 2008 ,Revised 13 June 2009 ,Accepted 16 June 2009.

References 

  1. Chin KM, Rubin LJ. Pulmonary arterial hypertension. J Am Coll Cardiol. 2008;51:1527–1538
  2. Rabinovitch M. Pathobiology of pulmonary hypertension. Annu Rev Pathol. 2007;2:369–399
  3. Zaiman A, Fijalkowska I, Hassoun PM, Tuder RM. One hundred years of research in the pathogenesis of pulmonary hypertension. Am J Respir Cell Mol Biol. 2005;33:425–431
  4. Humbert M, Morrell NW, Archer SL, Stenmark KR, MacLean MR, Lang IM, et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol. 2004;43(suppl):13S–24S
  5. Simonneau G, Galie N, Rubin LJ, Langleben D, Seeger W, Domenighetti G, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2004;43(suppl):5S–12S
  6. Rabinovitch M. Molecular pathogenesis of pulmonary arterial hypertension. J Clin Invest. 2008;118:2372–2379
  7. Witzenrath M, Ahrens B, Kube SM, Hocke AC, Rosseau S, Hamelmann E, et al. Allergic lung inflammation induces pulmonary vascular hyperresponsiveness. Eur Respir J. 2006;28:370–377
  8. Pabst R, Tschernig T. Perivascular capillaries in the lung: an important but neglected vascular bed in immune reactions?. J Allergy Clin Immunol. 2002;110:209–214
  9. Tormanen KR, Uller L, Persson CG, Erjefalt JS. Allergen exposure of mouse airways evokes remodeling of both bronchi and large pulmonary vessels. Am J Respir Crit Care Med. 2005;171:19–25
  10. Daley E, Emson C, Guignabert C, de Waal MR, Louten J, Kurup VP, et al. Pulmonary arterial remodeling induced by a Th2 immune response. J Exp Med. 2008;205:361–372
  11. Fajardo I, Svensson L, Bucht A, Pejler G. Increased levels of hypoxia-sensitive proteins in allergic airway inflammation. Am J Respir Crit Care Med. 2004;170:477–484
  12. Brinkmann V, Baumruker T. Pulmonary and vascular pharmacology of sphingosine 1-phosphate. Curr Opin Pharmacol. 2006;6:244–250
  13. Rivera J, Proia RL, Olivera A. The alliance of sphingosine-1-phosphate and its receptors in immunity. Nat Rev Immunol. 2008;8:753–763
  14. Roviezzo F, Di Lorenzo A, Bucci M, Brancaleone V, Vellecco V, De Nardo M, et al. Sphingosine-1-phosphate/sphingosine kinase pathway is involved in mouse airway hyperresponsiveness. Am J Respir Cell Mol Biol. 2007;36:757–762
  15. Oskeritzian CA, Milstien S, Spiegel S. Sphingosine-1-phosphate in allergic responses, asthma and anaphylaxis. Pharmacol Ther. 2007;115:390–399
  16. McVerry BJ, Garcia JG. In vitro and in vivo modulation of vascular barrier integrity by sphingosine 1-phosphate: mechanistic insights. Cell Signal. 2005;17:131–139
  17. Kurashima Y, Kunisawa J, Higuchi M, Gohda M, Ishikawa I, Takayama N, et al. Sphingosine 1-phosphate-mediated trafficking of pathogenic Th2 and mast cells for the control of food allergy. J Immunol. 2007;179:1577–1585
  18. Urata Y, Nishimura Y, Hirase T, Yokoyama M. Sphingosine 1-phosphate induces alpha-smooth muscle actin expression in lung fibroblasts via Rho-kinase. Kobe J Med Sci. 2005;51:17–27
  19. Lai WQ, Goh HH, Bao Z, Wong WS, Melendez AJ, Leung BP. The role of sphingosine kinase in a murine model of allergic asthma. J Immunol. 2008;180:4323–4329
  20. Idzko M, Hammad H, van Nimwegen M, Kool M, Muller T, Soullie T, et al. Local application of FTY720 to the lung abrogates experimental asthma by altering dendritic cell function. J Clin Invest. 2006;116:2935–2944
  21. Allende ML, Sasaki T, Kawai H, Olivera A, Mi Y, Echten-Deckert G, et al. Mice deficient in sphingosine kinase 1 are rendered lymphopenic by FTY720. J Biol Chem. 2004;279:52487–52492
  22. Foster PS, Hogan SP, Ramsay AJ, Matthaei KI, Young IG. Interleukin 5 deficiency abolishes eosinophilia, airways hyperreactivity, and lung damage in a mouse asthma model. J Exp Med. 1996;183:195–201
  23. Witzenrath M, Ahrens B, Kube SM, Braun A, Hoymann HG, Hocke AC, et al. Detection of allergen-induced airway hyperresponsiveness in isolated mouse lungs. Am J Physiol Lung Cell Mol Physiol. 2006;291:L466–L472
  24. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 2001;25:402–408
  25. Howard CV, Reed MG. Unbiased stereology. Three dimensional measurement in microscopy. Oxford: Bios Scientific publications; 1998;
  26. Nishiuma T, Nishimura Y, Okada T, Kuramoto E, Kotani Y, Jahangeer S, et al. Inhalation of sphingosine kinase inhibitor attenuates airway inflammation in asthmatic mouse model. Am J Physiol Lung Cell Mol Physiol. 2008;294:L1085–L1093
  27. Herz U, Braun A, Ruckert R, Renz H. Various immunological phenotypes are associated with increased airway responsiveness. Clin Exp Allergy. 1998;28:625–634
  28. Pfaff M, Powaga N, Akinci S, Schutz W, Banno Y, Wiegand S, et al. Activation of the SPHK/S1P signalling pathway is coupled to muscarinic receptor-dependent regulation of peripheral airways. Respir Res. 2005;6:48
  29. Kume H, Takeda N, Oguma T, Ito S, Kondo M, Ito Y, et al. Sphingosine 1-phosphate causes airway hyper-reactivity by rho-mediated myosin phosphatase inactivation. J Pharmacol Exp Ther. 2007;320:766–773
  30. Barbera JA, Peinado VI, Santos S. Pulmonary hypertension in chronic obstructive pulmonary disease. Eur Respir J. 2003;21:892–905
  31. Edmunds NJ, Woodward B. Effects of tumour necrosis factor-alpha on the coronary circulation of the rat isolated perfused heart: a potential role for thromboxane A2 and sphingosine. Br J Pharmacol. 1998;124:493–498
  32. Mechtcheriakova D, Wlachos A, Sobanov J, Kopp T, Reuschel R, Bornancin F, et al. Sphingosine 1-phosphate phosphatase 2 is induced during inflammatory responses. Cell Signal. 2007;19:748–760
  33. McVerry BJ, Garcia JG. In vitro and in vivo modulation of vascular barrier integrity by sphingosine 1-phosphate: mechanistic insights. Cell Signal. 2005;17:131–139

 Supported in part by grants from the German Research Foundation to M. W. (OP 86/7-1), the German Federal Ministry of Education and Research to N. S. (PROGRESS), and Flinders Medical Centre Foundation grant 2007-08 and Flinders University Faculty of Health Sciences grant 2006-07 to R. H.

 Disclosure of potential conflict of interest: R. V. Haberberger and I. Gibbins have received research support from the National Health and Medical Research Council (Australia). S. Runciman has received research support from the Australian Research Council. The rest of the authors have declared that they have no conflict of interest.

PII: S0091-6749(09)00987-7

doi: 10.1016/j.jaci.2009.06.034

The Journal of Allergy and Clinical Immunology
Volume 124, Issue 5 , Pages 933-941.e9 , November 2009

Article Tools

* Image Usage & Resolution